Kinetics Study on the Modification Process of Al2O3 Inclusions in High-Carbon Hard Wire Steel by Magnesium Treatment

The aim of the experiment in this work is to modify the Al2O3 inclusions in high-carbon hard wire steel by magnesium treatment. The general evolution process of inclusions in steel is: Al2O3 → MgO·Al2O3(MA) → MgO. The unreacted core model was used to study the modification process of inclusions. The results show that the complete modification time (tf) of inclusions is significantly shortened by the increase of magnesium content in molten steel. For Al2O3 inclusions with radius of 1 μm and Mg content in the range of 0.0005–0.0055%, the modification time of Al2O3 inclusions to MA decreased from 755 s to 25 s, which was reduced by 730 s. For Al2O3 inclusions with a radius of 1.5 μm and Mg content in the range of 0.001–0.0035%, the Al2O3 inclusions were completely modified to MgO inclusions from 592 s to 55 s. The Mg content in the molten steel increased 3.4-fold, and the time for complete modification of inclusions was shortened by about 10-fold. With the increase of Al and O content in molten steel, the complete modification time increased slightly, but the change was small. At the same time, the larger the radius of the unmodified inclusion is, the longer the complete modification time is. The tf of Al2O3 inclusions with a radius of 1 μm when modified to MA is 191 s, and the tf of Al2O3 inclusions with a radius of 2 μm when modified to MA is 765 s. According to the boundary conditions and the parameters of the unreacted core model, the MgO content in inclusions with different radius is calculated. The experimental results are essentially consistent with the kinetic calculation results.

Effect of Magnesium Treatment on the Hot Ductility of Ti-Bearing Peritectic Steel

Surface cracking is a major defect in the production of continuous casting slabs of peritectic steel. The difference in crystal structure between δ phase (before peritectic transformation of steel) and γ phase (after peritectic transformation) results in volume contraction, which leads to uneven cooling of mold and thus forming slab shells with different thicknesses. Then, coupled with the concentration of local stress, surface cracking occurs on slabs. In this paper, the effect of magnesium treatment on the hot ductility of Ti-bearing peritectic steel was studied, and the characteristics of solidification structure and TiN particles were analyzed. Magnesium treatment for Ti-bearing peritectic steel could significantly improve the hot ductility of continuous casting slabs by refining the original austenite structure. After the magnesium treatment, the average grain size of the original austenite of peritectic steel decreased by about 18.7%, and the size of Mg-rich TiN particles decreased by about 41%. In addition, the minimum reduction of area at the third brittle zone after the magnesium treatment was higher than 60%, and the fracture appearance changed from intergranular fracture to ductile fracture after the treatment. The contents of Mg, Ti, O, and N in peritectic steel and the cooling conditions were adjusted reasonably to promote the formation of highly dispersed Mg-rich TiN particles with a sufficient number density and a proper size in the initial solidification stage of peritectic steel, so as to induce the high-temperature δ-ferrite nucleation. Based on the fine δ structure formed by peritectic transformation, through the use of structure heredity and the pinning effect of secondary-precipitated nano TiN particles on the austenite grain boundary, a fine and dense original austenite structure could be obtained to improve the hot ductility of peritectic steel. Industrial tests showed that through the magnesium treatment, the surface cracks of Ti-bearing peritectic steel were effectively restrained, and the corner cracks of slabs were basically eliminated.

Magnesium and Pain

In terms of antinociceptive action, the main mode of action of magnesium involves its antagonist action at the N-methyl-d-aspartate (NMDA) receptor, which prevents central sensitization and attenuates preexisting pain hypersensitivity. Given the pivotal function of NMDA receptors in pain transduction, magnesium has been investigated in a variety of pain conditions. The oral and parenteral administration of magnesium via the intravenous, intrathecal, or epidural route may alleviate pain and perioperative anesthetic and analgesic requirements. These beneficial effects of magnesium therapy have also been reported in patients with neuropathic pain, such as malignancy-related neurologic symptoms, diabetic neuropathy, postherpetic neuralgia, and chemotherapy-induced peripheral neuropathy. In addition, magnesium treatment is reportedly able to alleviate fibromyalgia, dysmenorrhea, headaches, and acute migraine attacks. Although magnesium plays an evolving role in pain management, better understanding of the mechanism underlying its antinociceptive action and additional clinical studies is required to clarify its role as an adjuvant analgesic.

Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial

ABSTRACT Background Previous in vitro and in vivo studies indicate that enzymes that synthesize and metabolize vitamin D are magnesium dependent. Recent observational studies found that magnesium intake significantly interacted with vitamin D in relation to vitamin D status and risk of mortality. According to NHANES, 79% of US adults do not meet their Recommended Dietary Allowance of magnesium. Objectives The aim of this study was to test the hypothesis that magnesium supplementation differentially affects vitamin D metabolism dependent on baseline 25-hydroxyvitamin D [25(OH)D] concentration. Methods The study included 180 participants aged 40–85 y and is a National Cancer Institute independently funded ancillary study, nested within the Personalized Prevention of Colorectal Cancer Trial (PPCCT), which enrolled 250 participants. The PPCCT is a double-blind 2 × 2 factorial randomized controlled trial conducted in the Vanderbilt University Medical Center. Doses for both magnesium and placebo were customized based on baseline dietary intakes. Subjects were randomly assigned to treatments using a permuted-block randomization algorithm. Changes in plasma 25-hydroxyvitamin D3 [25(OH)D3], 25-hydroxyvitamin D2 [25(OH)D2], 1,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D2, and 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] were measured by liquid chromatography–mass spectrometry. Results The relations between magnesium treatment and plasma concentrations of 25(OH)D3, 25(OH)D2, and 24,25(OH)2D3 were significantly different dependent on the baseline concentrations of 25(OH)D, and significant interactions persisted after Bonferroni corrections. Magnesium supplementation increased the 25(OH)D3 concentration when baseline 25(OH)D concentrations were close to 30 ng/mL, but decreased it when baseline 25(OH)D was higher (from ∼30 to 50 ng/mL). Magnesium treatment significantly affected 24,25(OH)2D3 concentration when baseline 25(OH)D concentration was 50 ng/mL but not 30 ng/mL. On the other hand, magnesium treatment increased 25(OH)D2 as baseline 25(OH)D increased. Conclusion Our findings suggest that optimal magnesium status may be important for optimizing 25(OH)D status. This trial was registered at clinicaltrials.gov as NCT03265483.